Coherus Oncology (CHRS) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Coherus Oncology (CHRS) has outperformed Compass Therapeutics (CMPX) over the past year, losing 40.9% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -94.1% for CHRS. Compass Therapeutics is the larger company by market cap ($183.7 million vs $156.0 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CHRS | CMPX |
|---|---|---|
| Share price | $1.01 | $1.02 |
| Market cap | $156.05M | $183.69M |
| 1-day change | -1.94% | +2.19% |
| YTD return | -28.87% | -81.01% |
| 1-year return | -40.94% | -71.75% |
| 5-year return | -94.06% | -68.22% |
| EPS (TTM) | $-1.25 | $-0.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.62 | $6.88 |
| 52-week low | $1.01 | $0.829 |
| Distance from 52-week high | -61.39% | -85.17% |
| Analyst consensus | none | buy |
| Avg. price target upside | +667.33% | +434.31% |
| Average volume | 1.14M | 4.08M |
| Shares outstanding | 154.50M | 180.09M |
| Employees | 144 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CHRS has outperformed CMPX by 30.8 percentage points over the past year.
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Healthcare · Biotechnology · 144 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
CHRS vs CMPX FAQ
Which is bigger, Coherus Oncology or Compass Therapeutics?
Compass Therapeutics (CMPX) is larger, with a market capitalization of $183.69M compared with $156.05M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, CHRS or CMPX?
CHRS returned -40.94% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Coherus Oncology and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.